-
Mashup Score: 3
Treatment with vilobelimab reduced mortality at 28 to 60 days in patients with severe COVID-19 pneumonia without increasing infections, according to data presented at the European Respiratory Society International Congress.Vilobelimab (InflaRx) is a first-in-class monoclonal antibody that targets the complement activation product C5a that preserves the membrane attack complex.
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
Treatment with vilobelimab reduced mortality at 28 to 60 days in patients with severe COVID-19 pneumonia without increasing infections, according to data presented at the European Respiratory Society International Congress.Vilobelimab (InflaRx) is a first-in-class monoclonal antibody that targets the complement activation product C5a that preserves the membrane attack complex.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Among patients with severe #COVID19 #pneumonia, treatment with #vilobelimab reduced mortality at 28 to 60 days without increasing infections, according to data presented at #ERSCongress @InfectDisNews #PulmCC https://t.co/8o1fDmWG5e
-
-
Mashup Score: 0
Findings published in Chest highlighted the importance of routinely capturing treatment burden among individuals with cystic fibrosis in clinical trials.“The recent introduction of CFTR modulator therapies is transforming the outcomes and prognosis for many people with cystic fibrosis, with evidence emerging that their introduction is associated with reduced use of other treatments,”
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 1Ventilator-associated pneumonia ‘a major factor’ for poor prognosis in patients with COVID-19 - 2 year(s) ago
In a new study, ventilator-associated pneumonia-related mortality was higher among patients with COVID-19 compared with those without COVID-19, with more than 9% of overall mortality attributable to ventilator-associated pneumonia.“The occurrence of ventilator-associated pneumonia is a major factor of poor prognosis in patients with COVID-19,” Charles-Hervé Vacheron, MD, of the
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 1Ventilator-associated pneumonia ‘a major factor’ for poor prognosis in patients with COVID-19 - 2 year(s) ago
In a new study, ventilator-associated pneumonia-related mortality was higher among patients with COVID-19 compared with those without COVID-19, with more than 9% of overall mortality attributable to ventilator-associated pneumonia.“The occurrence of ventilator-associated pneumonia is a major factor of poor prognosis in patients with COVID-19,” Charles-Hervé Vacheron, MD, of the
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
A new study in @ATSBlueEditor evaluated ventilator-associated pneumonia in patients with and without #COVID19. Read more below @InfectDisNews #PulmCC https://t.co/WFNNM6LKj8
-
-
Mashup Score: 0Intravenous Vitamin C for Sepsis in the ICU | NEJM - 2 year(s) ago
Quick Take Video Summary from The New England Journal of Medicine — Intravenous Vitamin C for Sepsis in the ICU
Source: New England Journal of MedicineCategories: Critical Care, Latest HeadlinesTweet
-
Mashup Score: 0
The Healio Editors compiled the most-read news in pulmonology posted in May.Highlights include a study that found persistent symptoms following COVID-19 was common; a new clinical practice guideline from the American Thoracic Society on idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases; research presented at the ATS International Conference on asthma, COVID-19,
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
The Healio Editors compiled the most-read news in pulmonology posted in May.Highlights include a study that found persistent symptoms following COVID-19 was common; a new clinical practice guideline from the American Thoracic Society on idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases; research presented at the ATS International Conference on asthma, COVID-19,
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
The Healio Editors compiled a list of the most-read #pulmonology news published in May. Check out what Healio readers were most interested in below! #COVID19 #ATS2022 #asthma #IPF #PulmCC https://t.co/2Vo2MCWKwS
-
-
Mashup Score: 0Exposure to respirable crystalline silica tied to ‘unexpected surge’ in black lung disease - 2 year(s) ago
Higher levels of crystalline silica were found in the lung tissue of contemporary coal miners in the U.S. compared with the lung tissue of previous generations of coal miners, researchers reported in Annals of the American Thoracic Society. The results may help explain the recent increase in severe pneumoconiosis, often referred to as black lung disease, in coal miners in West Virginia, Virginia
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0Exposure to respirable crystalline silica tied to ‘unexpected surge’ in black lung disease - 2 year(s) ago
Higher levels of crystalline silica were found in the lung tissue of contemporary coal miners in the U.S. compared with the lung tissue of previous generations of coal miners, researchers reported in Annals of the American Thoracic Society. The results may help explain the recent increase in severe pneumoconiosis, often referred to as black lung disease, in coal miners in West Virginia, Virginia
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
New findings published in @AnnalsATS found that exposure to crystalline silica was associated with increased #blacklung disease in contemporary U.S. coal miners. #PulmCC https://t.co/wsWiYFn8Dh
-
Among patients with severe #COVID19 #pneumonia, treatment with #vilobelimab reduced mortality at 28 to 60 days without increasing infections, according to data presented at #ERSCongress @InfectDisNews #PulmCC https://t.co/3rrtNJCEki